Drug Development

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Articles

The US Food and Drug Administration issued an alert to healthcare professionals of a change in heparin manufacturing that is expected to decrease the drug's potency.

USP Issues New Quality Standards for Heparin

The 2009 Nobel Prize in Physiology or Medicine was awarded to three US researchers for the discovery of how chromosomes are protected from degradation by telomeres and the enzyme telomerase during cell division.

Nobel Prize Awarded for Research in the Role of a Chromosome Protector in Cell Division

GlaxoSmithKline (London), Novartis (Basel, Switzerland), sanofi Aventis (Paris), and Baxter International (Deerfield, IL) recently provided updates as to the development, manufacture, or shipment of pandemic (H1NI) vaccines.

Companies Update Pandemic (H1N1) Flu Vaccine Projects

Company and People Notes: GSK forms joint venture with China-based Jiangsu Walvax Biotech; Sigma-Aldrich appoints VP and board member; more...

Week of Oct. 5, 2009: Merck and CSL Sign Flu Vaccine Pact; Cardinal Health Names VP; More...

AAPS President offers hope and solutions for the industry's challenging future.

Looking Ahead: The Pharmaceutical-Science Industry

The nation's healtcare system needs an overhaul, but it has to be done right.

PhRMA's Stake in Reform

New nanotechnology-based delivery systems offer promise in drug delivery, particularly for anticancer therapeutics.

Delivering the Results in Drug-Based Nanotechnology

Applying a moisture protective barrier to tablet cores can help prevent degradation caused by ambient moisture.

Defining the ideal properties of a moisture protective, instant release film coating

The biopharmaceutical company Seattle Genetics (Bothell, WA) introduced a sugar-engineered antibody (SEA) technology that is designed to increase the potency of monoclonal antibodies through enhanced effector function.

Seattle Genetics Introduces Sugar-Engineered Antibody Technology

Company and People Notes: Boehringer Ingelheim will acquire Wyeth's animal health business; Amsterdam Molecular Therapeutics appoints CEO; more...

Ingredients